Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells

Cells degrade proteins either by proteasomes that clinically are targeted by for example bortezomib or carfilzomib, or by formation of autophagosomes and lysosomal degradation that can be inhibited by hydroxychloroquine (HCQ). Multiple myeloma is unique among cancers because proteasomal inhibition h...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranowska, Katarzyna, Misund, Kristine, Starheim, Kristian K., Holien, Toril, Johansson, Ida, Darvekar, Sagar, Buene, Glenn, Waage, Anders, Bjørkøy, Geir, Sundan, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342593/
https://www.ncbi.nlm.nih.gov/pubmed/27683126
http://dx.doi.org/10.18632/oncotarget.12226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342593/
https://www.ncbi.nlm.nih.gov/pubmed/27683126
http://dx.doi.org/10.18632/oncotarget.12226

Ejemplares similares